2015 American Transplant Congress
Efficacy, Safety and Pharmacokinetics of Once-Daily, MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus (Prograf®) in De Novo Kidney Transplant Recipient Sub-Groups: A 2 Year Phase 3 Randomized, Double-Blind, Double-Dummy, Trial
Differences in tacrolimus (tac) metabolism are evident in certain populations; in particular, lower tac bioavailability has been shown in females and black kidney transplant recipients…2015 American Transplant Congress
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…2015 American Transplant Congress
Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype
1University Medicine Charité, Berlin, Germany; 2Labor Berlin GmbH, Berlin, Germany.
Belatacept offers a new option for renal allograft recipients who are suffering from side effects of calcineurin inhibitor or mTOR. Such a conversion may result…2015 American Transplant Congress
Lipid Profiles Over 2 Years Follow-Up in De Novo Kidney Transplant Recipients Randomized to Once-Daily MeltDose® Tacrolimus (Envarsus® XR) Vs. Twice-Daily Tacrolimus (Prograf®): Results from a Phase 3, Double-Blind, Double-Dummy, Multicenter Trial
Cardiovascular disease (CVD) is a leading cause of death in kidney transplant recipients (KTR). Focusing on modifiable CVD risk factors is key to decreasing CVD-related…2015 American Transplant Congress
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation
Northwestern University, Chicago, IL.
Background: Despite being an effective strategy for overcoming ABO and HLA incompatibilities, desensitized kidney transplantation still has limitations. Early antibody mediated rejection (ABMR) may be…2015 American Transplant Congress
Comparison of Pharmacokinetics and Pharmacogenomics of Once-Daily Extended-Release MeltDose® Tacrolimus Tablets (Envarsus® XR) Vs. Twice-Daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-Over Study
The CYP3A5 genotype is the most significant genetic factor impacting tacrolimus (tac) metabolism; expresser's of this genotype require higher tac doses to achieve therapeutic tac…2015 American Transplant Congress
Ischemia-Induced Endoplasmic Reticulum Stress Regulates Autophagy to Determine the Severity of Liver Ischemia Reperfusion Injury
Both endoplasmic reticulum (ER) stress and autophagy have been implicated in the pathogenesis of ischemia and reperfusion injury (IRI). As essential cellular stress responses against…2015 American Transplant Congress
Liver Allografts from Living Donors Demonstrate High Expression of Hepatic Functional Genes Compared With Deceased Donors
1Surgery, UVA, Charlottesville, VA; 2Pathology, VCU, Richmond, VA.
Background: Donor shortage motivated alternative practices including living donor liver transplantation (LTx). This study aimed to identify molecular profiles and characteristics in living donor versus…2015 American Transplant Congress
Is the Pulsatile Kidney Preservation Machine a Vaulable Tool in Evaluating Kidney Suitability from Older Donors After Brain Death?
Introduction: Donors after Brain Death (DBD) older than 60 years old, have become 46.8% of our donor activity, with higher Discard Rate (DR). Assessment of…2015 American Transplant Congress
Remote Ischemic Perconditioning Induces Protection Against Hepatic Ischemia/Reperfusion Injury in Rats Via Downregualtion of Bax and Cleaved Caspase-3 Expression
Department of Surgery, Kyung Hee University, Seoul, Korea.
Purpose: The aim of this study was to determine whether remote ischemic preconditioning (rPeC) method can protect the hepatic IR injury in rat or not…
American Transplant Congress abstracts